Alicia completed a PhD in Biochemistry and Molecular Biology at Melbourne University in 2003 and subsequently worked as a post-doctoral fellow for many years in the US and Europe where she was focused on understanding signal transduction pathways in neurology and oncology. She has since retrained as a Nuclear Medicine Technologist allowing her to bring her extensive research skills into the clinical Nuclear Medicine realm.
Alicia is currently employed at the Peter MacCallum Cancer Centre where she is the lead Nuclear Medicine Technologist responsible for research conducted on the Total Body PET. Alicia has experience coordinating with clinical trials teams and other imaging societies such as ARTnet and SNMMI to qualify and maintain imaging equipment for research. She has also developed imaging protocols and been involved in numerous molecular imaging and radionuclide therapy clinical trials. Her passion is to expand the use of molecular biology to identify new biomarkers that can be exploited to create new radiopharmaceuticals to advance theranostics in oncology.
The Australian Epilepsy Project has seven MRI scanning sites across five states as part of a national network to provide epilepsy patients with access to advanced diagnostic testing that was otherwise
15 October 2025
In a world-first, an AI-powered model for disease progression of a common type of muscular dystrophy has been developed using full-body muscle-health scans collected by the FSHD Global Research Founda
09 October 2025
Neurodesk’s innovative ability to help researchers process and analyse massive neuroimaging datasets was recognised late last month at the 2025 National iAwards, presented in Adelaide. Neurodesk is
07 October 2025
When we read about this incredible Synchron technology, we think back to NIF’s support in its early days: NIF experts and the University of Melbourne’s 7T MRI instrument enabled the first
02 September 2025